Medical Care
Global Peripheral Arterial Disease (PAD) Therapeutics Market Research Report 2025
- Sep 06, 25
- ID: 492595
- Pages: 90
- Figures: 83
- Views: 3
This report aims to provide a comprehensive presentation of the global market for Peripheral Arterial Disease (PAD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peripheral Arterial Disease (PAD) Therapeutics.
The Peripheral Arterial Disease (PAD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peripheral Arterial Disease (PAD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peripheral Arterial Disease (PAD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Segment by Type
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peripheral Arterial Disease (PAD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Peripheral Arterial Disease (PAD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peripheral Arterial Disease (PAD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peripheral Arterial Disease (PAD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Segment by Type
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peripheral Arterial Disease (PAD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Anti-Platelet Drugs
1.2.3 Dual Antiplatelet Therapy Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Perspective (2020-2031)
2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Region
2.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Peripheral Arterial Disease (PAD) Therapeutics Market Dynamics
2.3.1 Peripheral Arterial Disease (PAD) Therapeutics Industry Trends
2.3.2 Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
2.3.3 Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
2.3.4 Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue
3.1.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
3.4 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio
3.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2024
3.5 Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics Head office and Area Served
3.6 Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Product and Application
3.7 Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Type
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Application
5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
6.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025)
6.4 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
7.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
9.2 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca Plc. (UK)
11.1.1 AstraZeneca Plc. (UK) Company Details
11.1.2 AstraZeneca Plc. (UK) Business Overview
11.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.1.5 AstraZeneca Plc. (UK) Recent Development
11.2 Bayer HealthCare Pharmaceuticals (Germany)
11.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Details
11.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
11.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
11.3 Bristol-Myers Squibb Company (US)
11.3.1 Bristol-Myers Squibb Company (US) Company Details
11.3.2 Bristol-Myers Squibb Company (US) Business Overview
11.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.3.5 Bristol-Myers Squibb Company (US) Recent Development
11.4 Merck & Co., Inc. (US)
11.4.1 Merck & Co., Inc. (US) Company Details
11.4.2 Merck & Co., Inc. (US) Business Overview
11.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.4.5 Merck & Co., Inc. (US) Recent Development
11.5 Proteon Therapeutics, Inc. (US)
11.5.1 Proteon Therapeutics, Inc. (US) Company Details
11.5.2 Proteon Therapeutics, Inc. (US) Business Overview
11.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.5.5 Proteon Therapeutics, Inc. (US) Recent Development
11.6 Sanofi S.A. (France)
11.6.1 Sanofi S.A. (France) Company Details
11.6.2 Sanofi S.A. (France) Business Overview
11.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.6.5 Sanofi S.A. (France) Recent Development
11.7 Symic Bio, Inc. (US)
11.7.1 Symic Bio, Inc. (US) Company Details
11.7.2 Symic Bio, Inc. (US) Business Overview
11.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.7.5 Symic Bio, Inc. (US) Recent Development
11.8 TheraVasc Inc. (US)
11.8.1 TheraVasc Inc. (US) Company Details
11.8.2 TheraVasc Inc. (US) Business Overview
11.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.8.5 TheraVasc Inc. (US) Recent Development
11.9 AnGes MG, Inc. (Japan)
11.9.1 AnGes MG, Inc. (Japan) Company Details
11.9.2 AnGes MG, Inc. (Japan) Business Overview
11.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.9.5 AnGes MG, Inc. (Japan) Recent Development
11.10 Athersys, Inc. (US)
11.10.1 Athersys, Inc. (US) Company Details
11.10.2 Athersys, Inc. (US) Business Overview
11.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.10.5 Athersys, Inc. (US) Recent Development
11.11 Betagenon AB (Sweden)
11.11.1 Betagenon AB (Sweden) Company Details
11.11.2 Betagenon AB (Sweden) Business Overview
11.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.11.4 Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.11.5 Betagenon AB (Sweden) Recent Development
11.12 miRagen Therapeutics, Inc. (US)
11.12.1 miRagen Therapeutics, Inc. (US) Company Details
11.12.2 miRagen Therapeutics, Inc. (US) Business Overview
11.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.12.4 miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.12.5 miRagen Therapeutics, Inc. (US) Recent Development
11.13 Multi Gene Vascular Systems Ltd (Israel)
11.13.1 Multi Gene Vascular Systems Ltd (Israel) Company Details
11.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview
11.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.13.4 Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Development
11.14 ViroMed Co. Ltd. (Korea)
11.14.1 ViroMed Co. Ltd. (Korea) Company Details
11.14.2 ViroMed Co. Ltd. (Korea) Business Overview
11.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.14.4 ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.14.5 ViroMed Co. Ltd. (Korea) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Anti-Platelet Drugs
1.2.3 Dual Antiplatelet Therapy Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Perspective (2020-2031)
2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Region
2.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Peripheral Arterial Disease (PAD) Therapeutics Market Dynamics
2.3.1 Peripheral Arterial Disease (PAD) Therapeutics Industry Trends
2.3.2 Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
2.3.3 Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
2.3.4 Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue
3.1.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
3.4 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio
3.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2024
3.5 Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics Head office and Area Served
3.6 Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Product and Application
3.7 Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Type
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Application
5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
6.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025)
6.4 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
7.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
9.2 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca Plc. (UK)
11.1.1 AstraZeneca Plc. (UK) Company Details
11.1.2 AstraZeneca Plc. (UK) Business Overview
11.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.1.5 AstraZeneca Plc. (UK) Recent Development
11.2 Bayer HealthCare Pharmaceuticals (Germany)
11.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Details
11.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
11.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
11.3 Bristol-Myers Squibb Company (US)
11.3.1 Bristol-Myers Squibb Company (US) Company Details
11.3.2 Bristol-Myers Squibb Company (US) Business Overview
11.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.3.5 Bristol-Myers Squibb Company (US) Recent Development
11.4 Merck & Co., Inc. (US)
11.4.1 Merck & Co., Inc. (US) Company Details
11.4.2 Merck & Co., Inc. (US) Business Overview
11.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.4.5 Merck & Co., Inc. (US) Recent Development
11.5 Proteon Therapeutics, Inc. (US)
11.5.1 Proteon Therapeutics, Inc. (US) Company Details
11.5.2 Proteon Therapeutics, Inc. (US) Business Overview
11.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.5.5 Proteon Therapeutics, Inc. (US) Recent Development
11.6 Sanofi S.A. (France)
11.6.1 Sanofi S.A. (France) Company Details
11.6.2 Sanofi S.A. (France) Business Overview
11.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.6.5 Sanofi S.A. (France) Recent Development
11.7 Symic Bio, Inc. (US)
11.7.1 Symic Bio, Inc. (US) Company Details
11.7.2 Symic Bio, Inc. (US) Business Overview
11.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.7.5 Symic Bio, Inc. (US) Recent Development
11.8 TheraVasc Inc. (US)
11.8.1 TheraVasc Inc. (US) Company Details
11.8.2 TheraVasc Inc. (US) Business Overview
11.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.8.5 TheraVasc Inc. (US) Recent Development
11.9 AnGes MG, Inc. (Japan)
11.9.1 AnGes MG, Inc. (Japan) Company Details
11.9.2 AnGes MG, Inc. (Japan) Business Overview
11.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.9.5 AnGes MG, Inc. (Japan) Recent Development
11.10 Athersys, Inc. (US)
11.10.1 Athersys, Inc. (US) Company Details
11.10.2 Athersys, Inc. (US) Business Overview
11.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.10.5 Athersys, Inc. (US) Recent Development
11.11 Betagenon AB (Sweden)
11.11.1 Betagenon AB (Sweden) Company Details
11.11.2 Betagenon AB (Sweden) Business Overview
11.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.11.4 Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.11.5 Betagenon AB (Sweden) Recent Development
11.12 miRagen Therapeutics, Inc. (US)
11.12.1 miRagen Therapeutics, Inc. (US) Company Details
11.12.2 miRagen Therapeutics, Inc. (US) Business Overview
11.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.12.4 miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.12.5 miRagen Therapeutics, Inc. (US) Recent Development
11.13 Multi Gene Vascular Systems Ltd (Israel)
11.13.1 Multi Gene Vascular Systems Ltd (Israel) Company Details
11.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview
11.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.13.4 Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Development
11.14 ViroMed Co. Ltd. (Korea)
11.14.1 ViroMed Co. Ltd. (Korea) Company Details
11.14.2 ViroMed Co. Ltd. (Korea) Business Overview
11.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.14.4 ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
11.14.5 ViroMed Co. Ltd. (Korea) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Anti-Platelet Drugs
Table 3. Key Players of Dual Antiplatelet Therapy Drugs
Table 4. Key Players of Others
Table 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2020-2025)
Table 9. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2026-2031)
Table 11. Peripheral Arterial Disease (PAD) Therapeutics Market Trends
Table 12. Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
Table 13. Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
Table 14. Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
Table 15. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players (2020-2025)
Table 17. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2024)
Table 18. Ranking of Global Top Peripheral Arterial Disease (PAD) Therapeutics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Product and Application
Table 22. Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2020-2025)
Table 26. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2026-2031)
Table 28. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2020-2025)
Table 30. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2026-2031)
Table 32. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. AstraZeneca Plc. (UK) Company Details
Table 48. AstraZeneca Plc. (UK) Business Overview
Table 49. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 50. AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 51. AstraZeneca Plc. (UK) Recent Development
Table 52. Bayer HealthCare Pharmaceuticals (Germany) Company Details
Table 53. Bayer HealthCare Pharmaceuticals (Germany) Business Overview
Table 54. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 55. Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 56. Bayer HealthCare Pharmaceuticals (Germany) Recent Development
Table 57. Bristol-Myers Squibb Company (US) Company Details
Table 58. Bristol-Myers Squibb Company (US) Business Overview
Table 59. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 60. Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 61. Bristol-Myers Squibb Company (US) Recent Development
Table 62. Merck & Co., Inc. (US) Company Details
Table 63. Merck & Co., Inc. (US) Business Overview
Table 64. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 65. Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Merck & Co., Inc. (US) Recent Development
Table 67. Proteon Therapeutics, Inc. (US) Company Details
Table 68. Proteon Therapeutics, Inc. (US) Business Overview
Table 69. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 70. Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Proteon Therapeutics, Inc. (US) Recent Development
Table 72. Sanofi S.A. (France) Company Details
Table 73. Sanofi S.A. (France) Business Overview
Table 74. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 75. Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 76. Sanofi S.A. (France) Recent Development
Table 77. Symic Bio, Inc. (US) Company Details
Table 78. Symic Bio, Inc. (US) Business Overview
Table 79. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 80. Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 81. Symic Bio, Inc. (US) Recent Development
Table 82. TheraVasc Inc. (US) Company Details
Table 83. TheraVasc Inc. (US) Business Overview
Table 84. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 85. TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 86. TheraVasc Inc. (US) Recent Development
Table 87. AnGes MG, Inc. (Japan) Company Details
Table 88. AnGes MG, Inc. (Japan) Business Overview
Table 89. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 90. AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 91. AnGes MG, Inc. (Japan) Recent Development
Table 92. Athersys, Inc. (US) Company Details
Table 93. Athersys, Inc. (US) Business Overview
Table 94. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 95. Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 96. Athersys, Inc. (US) Recent Development
Table 97. Betagenon AB (Sweden) Company Details
Table 98. Betagenon AB (Sweden) Business Overview
Table 99. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 100. Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 101. Betagenon AB (Sweden) Recent Development
Table 102. miRagen Therapeutics, Inc. (US) Company Details
Table 103. miRagen Therapeutics, Inc. (US) Business Overview
Table 104. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 105. miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 106. miRagen Therapeutics, Inc. (US) Recent Development
Table 107. Multi Gene Vascular Systems Ltd (Israel) Company Details
Table 108. Multi Gene Vascular Systems Ltd (Israel) Business Overview
Table 109. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 110. Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 111. Multi Gene Vascular Systems Ltd (Israel) Recent Development
Table 112. ViroMed Co. Ltd. (Korea) Company Details
Table 113. ViroMed Co. Ltd. (Korea) Business Overview
Table 114. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 115. ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 116. ViroMed Co. Ltd. (Korea) Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
Table 120. Authors List of This Report
List of Figures
Figure 1. Peripheral Arterial Disease (PAD) Therapeutics Picture
Figure 2. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Anti-Platelet Drugs Features
Figure 5. Dual Antiplatelet Therapy Drugs Features
Figure 6. Others Features
Figure 7. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Peripheral Arterial Disease (PAD) Therapeutics Report Years Considered
Figure 13. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region: 2024 VS 2031
Figure 16. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players in 2024
Figure 17. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2024
Figure 19. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2020-2031)
Figure 21. United States Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2020-2031)
Figure 25. Germany Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2020-2031)
Figure 33. China Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2020-2031)
Figure 41. Mexico Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2020-2031)
Figure 45. Turkey Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. AstraZeneca Plc. (UK) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 49. Bayer HealthCare Pharmaceuticals (Germany) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 50. Bristol-Myers Squibb Company (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 51. Merck & Co., Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 52. Proteon Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 53. Sanofi S.A. (France) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 54. Symic Bio, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 55. TheraVasc Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 56. AnGes MG, Inc. (Japan) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 57. Athersys, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 58. Betagenon AB (Sweden) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 59. miRagen Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 60. Multi Gene Vascular Systems Ltd (Israel) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 61. ViroMed Co. Ltd. (Korea) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Table 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Anti-Platelet Drugs
Table 3. Key Players of Dual Antiplatelet Therapy Drugs
Table 4. Key Players of Others
Table 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2020-2025)
Table 9. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2026-2031)
Table 11. Peripheral Arterial Disease (PAD) Therapeutics Market Trends
Table 12. Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
Table 13. Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
Table 14. Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
Table 15. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players (2020-2025)
Table 17. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2024)
Table 18. Ranking of Global Top Peripheral Arterial Disease (PAD) Therapeutics Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Headquarters and Area Served
Table 21. Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Product and Application
Table 22. Global Key Players of Peripheral Arterial Disease (PAD) Therapeutics, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2020-2025)
Table 26. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2026-2031)
Table 28. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2020-2025)
Table 30. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2026-2031)
Table 32. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. AstraZeneca Plc. (UK) Company Details
Table 48. AstraZeneca Plc. (UK) Business Overview
Table 49. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 50. AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 51. AstraZeneca Plc. (UK) Recent Development
Table 52. Bayer HealthCare Pharmaceuticals (Germany) Company Details
Table 53. Bayer HealthCare Pharmaceuticals (Germany) Business Overview
Table 54. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 55. Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 56. Bayer HealthCare Pharmaceuticals (Germany) Recent Development
Table 57. Bristol-Myers Squibb Company (US) Company Details
Table 58. Bristol-Myers Squibb Company (US) Business Overview
Table 59. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 60. Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 61. Bristol-Myers Squibb Company (US) Recent Development
Table 62. Merck & Co., Inc. (US) Company Details
Table 63. Merck & Co., Inc. (US) Business Overview
Table 64. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 65. Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 66. Merck & Co., Inc. (US) Recent Development
Table 67. Proteon Therapeutics, Inc. (US) Company Details
Table 68. Proteon Therapeutics, Inc. (US) Business Overview
Table 69. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 70. Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 71. Proteon Therapeutics, Inc. (US) Recent Development
Table 72. Sanofi S.A. (France) Company Details
Table 73. Sanofi S.A. (France) Business Overview
Table 74. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 75. Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 76. Sanofi S.A. (France) Recent Development
Table 77. Symic Bio, Inc. (US) Company Details
Table 78. Symic Bio, Inc. (US) Business Overview
Table 79. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 80. Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 81. Symic Bio, Inc. (US) Recent Development
Table 82. TheraVasc Inc. (US) Company Details
Table 83. TheraVasc Inc. (US) Business Overview
Table 84. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 85. TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 86. TheraVasc Inc. (US) Recent Development
Table 87. AnGes MG, Inc. (Japan) Company Details
Table 88. AnGes MG, Inc. (Japan) Business Overview
Table 89. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 90. AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 91. AnGes MG, Inc. (Japan) Recent Development
Table 92. Athersys, Inc. (US) Company Details
Table 93. Athersys, Inc. (US) Business Overview
Table 94. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 95. Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 96. Athersys, Inc. (US) Recent Development
Table 97. Betagenon AB (Sweden) Company Details
Table 98. Betagenon AB (Sweden) Business Overview
Table 99. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 100. Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 101. Betagenon AB (Sweden) Recent Development
Table 102. miRagen Therapeutics, Inc. (US) Company Details
Table 103. miRagen Therapeutics, Inc. (US) Business Overview
Table 104. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 105. miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 106. miRagen Therapeutics, Inc. (US) Recent Development
Table 107. Multi Gene Vascular Systems Ltd (Israel) Company Details
Table 108. Multi Gene Vascular Systems Ltd (Israel) Business Overview
Table 109. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 110. Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 111. Multi Gene Vascular Systems Ltd (Israel) Recent Development
Table 112. ViroMed Co. Ltd. (Korea) Company Details
Table 113. ViroMed Co. Ltd. (Korea) Business Overview
Table 114. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 115. ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025) & (US$ Million)
Table 116. ViroMed Co. Ltd. (Korea) Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
Table 120. Authors List of This Report
List of Figures
Figure 1. Peripheral Arterial Disease (PAD) Therapeutics Picture
Figure 2. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Anti-Platelet Drugs Features
Figure 5. Dual Antiplatelet Therapy Drugs Features
Figure 6. Others Features
Figure 7. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Others Case Studies
Figure 12. Peripheral Arterial Disease (PAD) Therapeutics Report Years Considered
Figure 13. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region: 2024 VS 2031
Figure 16. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players in 2024
Figure 17. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2024
Figure 19. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2020-2031)
Figure 21. United States Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2020-2031)
Figure 25. Germany Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2020-2031)
Figure 33. China Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2020-2031)
Figure 41. Mexico Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2020-2031)
Figure 45. Turkey Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. AstraZeneca Plc. (UK) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 49. Bayer HealthCare Pharmaceuticals (Germany) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 50. Bristol-Myers Squibb Company (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 51. Merck & Co., Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 52. Proteon Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 53. Sanofi S.A. (France) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 54. Symic Bio, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 55. TheraVasc Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 56. AnGes MG, Inc. (Japan) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 57. Athersys, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 58. Betagenon AB (Sweden) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 59. miRagen Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 60. Multi Gene Vascular Systems Ltd (Israel) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 61. ViroMed Co. Ltd. (Korea) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Outdoor Shed Market Research Report 2025
Sep 09, 25
Global Residential Outdoor Cabinet Market Research Report 2025
Sep 09, 25
Global Outdoor Storage Cabinet Market Research Report 2025
Sep 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232